Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 15/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.34 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.34 |
| ▸ | CD69 | Q07108 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23943307 | 0.96 | SELE (0.57) | SELEMAPK1ALDH1A1THRBLGALS8 | |
| SCHEMBL21206351 | 0.92 | SELE (0.59) | SELEMAPK1ALDH1A1THRBLGALS8 | |
| SCHEMBL21206347 | 0.91 | SELE (0.69) | SELEMAPK1ALDH1A1THRB | |
| SCHEMBL16661823 | 0.91 | SELE (0.60) | SELEMAPK1ALDH1A1THRBLGALS8 | |
| SCHEMBL15070100 | 0.91 | SELE (0.60) | SELEMAPK1ALDH1A1THRBLGALS8 | |
| SCHEMBL17881667 | 0.91 | SELE (0.60) | SELEMAPK1ALDH1A1THRBLGALS8 | |
| SCHEMBL25446767 | 0.88 | SELE (0.57) | SELEMAPK1ALDH1A1THRB | |
| SCHEMBL23943277 | 0.86 | SELE (0.67) | SELEMAPK1ALDH1A1THRB | |
| SCHEMBL19939764 | 0.85 | SELE (0.74) | SELEMAPK1LGALS8LGALS3LGALS4 | |
| SCHEMBL16659822 | 0.85 | SELE (0.74) | SELEMAPK1LGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072625-B2 | Highly potent multimeric e-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20190233458-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233458-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | SELE 1/4885MAPK1 3831/4885ALDH1A1 759/4885 |
| US-11072625-B2 | Highly potent multimeric e-selectin antagonists | SELE, SELP, SELPLG | SELE 1/4885MAPK1 3949/4885ALDH1A1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.